Skip to main content

Advertisement

Log in

Tamoxifen administration and the risk of Parkinsonism

  • Letter to the Editor
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Lai SW (2018) Tamoxifen administration and risk of Parkinson’s disease. Eur J Clin Pharmacol. https://doi.org/10.1007/s00228-018-2553-y

  2. Montastruc F, Khosrow-Khavar F, de Germay S, Renoux C, Rousseau V, Durrieu G, Montastruc M, Rascol O, Sommet A, Lapeyre-Mestre M, Benevent J, Montastruc JL (2018) Tamoxifen and the risk of parkinsonism: a case/non-case study. Eur J Clin Pharmacol 74:1181–1184

    Article  CAS  PubMed  Google Scholar 

  3. Latourelle JC, Dybdahl M, Destefano AL, Myers RH, Lash TL (2010) Risk of Parkinson's disease after tamoxifen treatment. BMC Neurol 10:23

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Lin HF, Liao KF, Chang CM, Lin CL, Lai SW (2018) Tamoxifen usage correlates with increased risk of Parkinson's disease in older women with breast cancer: a case-control study in Taiwan. Eur J Clin Pharmacol 74:99–107

    Article  CAS  PubMed  Google Scholar 

  5. Hong CT, Chan L, Hu CJ, Lin CM, Hsu CY, Lin MC (2017) Tamoxifen and the risk of Parkinson’s disease in female patients with breast cancer in Asian people: a nationwide population-based study. J Breast Cancer 20:356–360

    Article  PubMed  PubMed Central  Google Scholar 

  6. Faillie JL, Montastruc F, Montastruc JL, Pariente A (2016) Pharmacoepidemiology and its input to pharmacovigilance. Therapie 71:211–216

    Article  PubMed  Google Scholar 

  7. Faillie JL (2018) Case-non case studies: principles, methods, bias and interpretation. Therapie 73:247–255

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jean-Louis Montastruc.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Montastruc, F., Khosrow-Khavar, F., Sommet, A. et al. Tamoxifen administration and the risk of Parkinsonism. Eur J Clin Pharmacol 75, 135–136 (2019). https://doi.org/10.1007/s00228-018-2554-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-018-2554-x

Navigation